![Chetan Lathia](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chetan Lathia
Consigliere Generale presso BIOXCEL THERAPEUTICS, INC.
Posizioni attive di Chetan Lathia
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOXCEL THERAPEUTICS, INC. | Consigliere Generale | - | - |
Storia della carriera di Chetan Lathia
Precedenti posizioni note di Chetan Lathia
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | - |
Formazione di Chetan Lathia
Virginia Commonwealth University | Doctorate Degree |
L. M. College of Pharmacy | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
India | 2 |
Posizioni
Corporate Officer/Principal | 2 |
General Counsel | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
BIOXCEL THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Chetan Lathia
- Esperienza